Beyond application, the market is further stratified by types of ELISA testing services, each reflecting distinct assay architectures and analytical objectives. Direct ELISA, where antigen is immobilized and detected by enzyme‑labeled primary antibodies, serves straightforward antigen quantification and contributes modestly to service revenue due to its limited scope. Indirect ELISA, employing a secondary enzyme‑conjugated antibody, offers amplified signal and flexibility, capturing a larger share of clinical and research contracts. Sandwich ELISA, the most widely adopted format, utilizes capture and detection antibodies to measure complex antigens with high specificity, driving the bulk of market volume across all application categories. Competitive (or inhibition) ELISA, used for small molecule detection where direct binding is impractical, sustains niche demand in food safety and environmental testing. Finally, multiplex ELISA platforms enable simultaneous quantification of multiple analytes, increasingly adopted in pharmaceutical R&D for efficiency gains. These service types collectively define the market taxonomy and influence pricing, capacity planning, and technology investment decisions.